StrategX Elements Corp. Announces $1.5M Private Placement Resulting in Creation of a Control Person

StrategX Elements Corp. (CSE: STGX) ("StrategX" or the "Company"), announces its intention to complete a non-brokered private placement of up to 15,000,000 common shares (the "Shares") at a purchase price of $0.10 per Share to raise gross proceeds of up to $1,500,000. The proceeds received from the sale of the Shares will be used to fund a drill program on the Company's Nagvaak Property and for general working capital purposes. When issued, the Shares will be subject to a four-month-and-one-day hold period under securities laws in Canada.

It is proposed that all of the Shares will be purchased by David Haig Associates Inc. ("DHA"), which will result in DHA holding 28.5% of the issued shares of the Company, on a non-diluted basis. As such, DHA will become a new control person. This financing is subject to CSE approval. Pursuant to CSE policies, the creation of a new control person is subject to shareholder approval which may be obtained by way of written consent of shareholders holding 50% + 1 of the issued shares of the Company. This private placement is expected to close as soon as all approvals have been obtained.

DHA is a private company controlled by David Haig, a director of the Company. Mr. Haig's participation in this private placement through DHA is considered a "related party transaction" pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is exempt from the requirements to obtain a formal valuation in reliance of section 5.5(b) of MI 61-101 in that the Company is not listed or quoted on a senior stock exchange specified therein. The Company is also exempt from the requirements to obtain shareholder approval in reliance of section 5.7(b) of MI 61-101 in that the Company is not listed or quoted on a senior stock exchange specified therein, the value of the financing does not exceed $2,500,000, the Company has one or more independent directors in respect of this financing who are not employees of the Company and at least 2/3 of those directors have approved the financing.

About StrategX
StrategX is a Canadian-based exploration company focused on discovering critical metals in northern Canada. With five strategic projects situated on the East Arm of the Great Slave Lake, Northwest Territories and the Melville Peninsula, Nunavut, we're leading discovery in untapped regions. This first-mover advantage in underexplored regions presents a unique opportunity for investors to be part of multiple discoveries and the development of new districts for critical metals essential for the global green energy shift. For updates and the latest insights, explore our Investor Portal.

On Behalf of the Board of Directors

Darren G. Bahrey
CEO, President & Director

For further information, please contact:

StrategX Elements Corp.
info@strategXcorp.com
Phone: 778.231.2767

For further information about the Company, please visit our website at www.strategXcorp.com.

Neither the Canadian Securities Exchange nor its regulation services accept responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information
All statements included in this press release that address activities, events, or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections, and other forward-looking statements will prove inaccurate, certain of which are beyond the Company's control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/210180

News Provided by Newsfile via QuoteMedia

StrategX Elements STGX:CC CSE:STGX Base Metals Investing

STGX:CC

StrategX Elements Corp. Announces $4.5M Charity Flow-Through Private Placement

StrategX Elements Corp. (CSE: STGX) ("StrategX" or the "Company"), announces that it proposes to undertake an up to $4,500,000 non-brokered private placement of flow-through shares (the "Charity FT Shares") to be sold to charitable purchasers at a price of $0.30 per Charity FT Share. The gross proceeds received from the sale of the Charity FT Shares will be used for work programs on the Company's exploration properties. All securities issued and sold under this financing will be subject to a four-month-and-one-day hold period under securities laws in Canada. The Company expects to complete this Charity FT Share financing on or before June 24, 2024.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

StrategX Elements Corp. Announces Closing of Non-Brokered Private Placement

StrategX Elements Corp. (CSE: STGX) ("StrategX" or the "Company"), announces it has closed a non-brokered private placement previously announced on March 26, 2024, and has issued 2,900,000 common shares for gross proceeds of $290,000. In connection with the financing, the Company paid a total of $12,000 as finder's fees. All shares issued under the private placement are subject to a hold period expiring September 4, 2024, in accordance with applicable securities laws and the policies of the CSE.

About StrategX
StrategX is a Canadian-based exploration company focused on discovering critical metals in northern Canada. With five strategic projects situated on the East Arm of the Great Slave Lake, Northwest Territories and the Melville Peninsula, Nunavut, we're leading discovery in untapped regions. This first-mover advantage in underexplored regions presents a unique opportunity for investors to be part of multiple discoveries and the development of new districts for critical metals essential for the global green energy shift. For updates and the latest insights, explore our Investor Portal.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

StrategX Elements Corp. Announces Executive Change and New Board Member

StrategX Elements Corp. (CSE: STGX) ("StrategX" or the "Company") announces a transition in leadership with the departure of Andrea Yuan from her role as Chief Financial Officer ("CFO") to pursue other endeavours. Ms. Yuan was instrumental in navigating the Company through its IPO process and subsequent listing on the CSE. The Board and CEO would like to thank Andrea for her efforts and contributions over the past few years. Ryan McEachern, a director of the Company and previous Chair of the Audit Committee, has been appointed interim CFO effective immediately. Mr. McEachern brings a wealth of experience to the role, ensuring a smooth transition. Concurrently, he has stepped down from the Company's Audit Committee position.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

StrategX Increases the Size of the Nagvaak Critical Metals Discovery on the Melville Peninsula in Northern Canada

StrategX Elements Corp. (CSE: STGX) ("StrategX" or the "Company") is pleased to announce a considerable advancement reporting additional positive assay results for surface rock samples and drill core from its 100%-owned (2,665-hectare) Nagvaak property. This confirms the discovery of additional zones of critical metals on surface and at depth. These results expand the length of the mineralized corridor to over 6 kilometres and correlate well with previously interpreted geophysical anomalies. The exploration team is focused on prioritizing drill targets and preparing a first phase of drilling to potentially define a large polymetallic deposit in nickel, copper, vanadium, molybdenum, zinc, and precious metals at Nagvaak.

SAMPLE	Au	Pt	Pd	Ag	Cu	Mo	Ni	V	V₂O₅	Zn
NF22 001	0.01	0.00	0.01	2.16	0.03	0.00	0.03	0.01	0.02	0.01
NF22 002	0.02	0.01	0.08	7.93	0.24	0.11	0.24	0.33	0.59	0.04
NF22 012	0.03	0.02	0.09	7.85	0.14	0.03	0.17	0.21	0.38	0.07
NF22 013	0.01	0.01	0.02	2.43	0.04	0.05	0.04	0.14	0.25	13.05
NF22 014	0.02	0.02	0.12	11.70	0.23	0.10	0.21	0.28	0.50	0.16
NF22 015	0.02	0.00	0.23	8.14	0.25	0.00	0.37	0.03	0.06	0.11
NF22 016	0.06	0.01	0.04	15.40	0.06	0.05	0.04	0.15	0.27	0.01
NF22 017	0.11	0.01	0.04	10.50	0.07	0.02	0.05	0.18	0.32	4.31
NF22 018	0.00	0.00	0.05	7.30	0.04	0.03	0.04	0.16	0.28	0.02
NF22 019	0.00	0.13	0.04	10.20	0.01	0.03	0.01	0.21	0.37	0.02
NF22 020	0.05	0.02	0.54	18.45	0.49	0.04	0.08	0.29	0.52	0.10
NF22 021	0.09	0.07	0.27	11.90	0.42	0.09	0.28	0.37	0.67	0.07
NF22 022	0.24	0.02	0.22	3.18	0.15	0.01	0.29	0.36	0.64	0.08
NF22 024	0.00	0.03	0.05	1.76	0.13	0.05	0.21	0.31	0.54	0.06
NF22 025	0.00	0.02	0.06	2.30	0.13	0.04	0.48	0.26	0.47	0.02
NF22 026	0.01	0.07	0.09	2.26	0.16	0.03	0.26	0.20	0.35	0.22
NF22 027	0.03	0.03	0.11	3.59	0.19	0.03	0.20	0.18	0.32	0.03
NF22 028	0.01	0.01	0.11	2.78	0.22	0.03	0.34	0.21	0.37	0.93
NF22 029	0.00	0.03	0.07	4.95	0.17	0.04	0.11	0.22	0.40	0.03
NF22 030	0.00	0.04	0.06	5.74	0.18	0.02	0.06	0.26	0.47	0.05
NF22 031	0.01	0.01	0.08	3.23	0.14	0.05	0.17	0.17	0.30	0.03
NF22 032	0.00	0.02	0.12	3.24	0.14	0.02	0.14	0.38	0.67	0.02
NF22 033	0.01	0.00	0.02	7.23	0.22	0.03	0.21	0.16	0.28	0.82
NF22 034	0.01	0.01	0.08	7.70	0.40	0.19	0.21	0.26	0.47	0.11
NF22 035	0.01	0.00	0.00	6.87	0.44	0.03	0.33	0.20	0.36	0.01
NF22 036	0.02	0.14	0.10	1.81	0.17	0.04	0.35	0.50	0.89	0.02
NF22 037	0.03	0.01	0.02	2.72	0.13	0.03	0.13	0.14	0.25	0.43
NF22 038	0.03	0.06	0.04	4.10	0.17	0.08	0.20	0.41	0.74	0.02
NF22 039	0.04	0.03	0.09	6.74	0.31	0.04	0.13	0.22	0.40	0.71
NF22 040	0.02	0.01	0.03	6.32	0.23	0.03	0.24	0.32	0.58	0.03
NF22 041	0.03	0.01	0.06	4.99	0.22	0.07	0.30	0.27	0.48	0.02
NF22 042	0.21	0.03	0.01	4.44	0.15	0.06	0.46	0.40	0.71	0.01
NF22 043	0.01	0.00	0.13	16.00	0.31	0.02	0.26	0.12	0.21	0.10
NF22 044	0.03	0.02	0.05	5.34	0.25	0.04	0.36	0.24	0.43	0.01
NF22 045	0.26	0.03	0.15	2.05	0.14	0.05	0.25	0.30	0.54	0.05
NF22 201	0.13	0.03	0.21	44.50	1.09	0.03	0.14	0.28	0.49	1.38
NF22 202	0.02	0.02	0.03	15.35	0.37	0.07	0.22	0.31	0.56	0.03
NF22 203	0.01	0.00	0.05	12.35	0.05	0.04	0.05	0.14	0.24	0.18
NF22 204	0.01	0.00	0.05	8.72	0.07	0.03	0.06	0.16	0.29	0.27
NF22 205	0.00	0.01	0.04	4.72	0.06	0.01	0.16	0.12	0.21	0.13
NF22 206	0.01	0.00	0.07	11.00	0.13	0.03	0.18	0.25	0.44	1.20
NF22 207	0.00	0.00	0.03	7.75	0.18	0.05	0.08	0.18	0.32	0.67
NF22 208	0.01	0.04	0.02	10.65	0.34	0.02	0.27	0.27	0.47	0.22
NF22 209	0.00	0.00	0.00	1.20	0.03	0.00	0.01	0.02	0.04	0.01
NF22 210	0.00	0.01	0.02	2.65	0.07	0.01	0.15	0.08	0.14	0.01

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Ascendant Resources Announces Results of Annual General Meeting of Shareholders

Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting resultsof the Company's 2024 Annual General Shareholders' Meeting (the "Meeting") held on June 13, 2024, in Toronto, Ontario

A total of 51,497,589 common shares were voted at the Meeting, representing 27.59% of the votes attached to all outstanding common shares of the Company. All matterspresented for shareholder approval at the Meeting were duly authorized and approved as follows:

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Romios Begins Field Work to Follow-Up New Satellite Image Study by Photosat Outlining Significant Alteration Zones at the Kinkaid Copper-Gold-Silver Property, Nevada, USA

Romios Gold Resources Inc. (TSXV: RG) (OTCQB: RMIOF) (FSE: D4R) ("Romios Gold" or the "Company") is pleased to report that Photosat has recently completed an in-depth, advanced re-interpretation of the previously reported Short Wave Infrared (SWIR) satellite image study that outlined the specific alteration minerals associated with mineralization on Romios' Kinkaid property in Mineral County, Nevada.

This new work used proprietary Deep Learning Technology to differentiate the types of sericite associated with the known mineralized structures and then outlined the same signature on several major, previously unrecognized, linear alteration zones potentially associated with additional mineralized vein systems.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

End of the BAPE Public Information Period

Falco Resources Ltd. (TSX.V: FPC) (" Falco " or the " Corporation ") would like to thank all those who participated and enriched the discussions during the public information period of the Bureau d'audiences publiques sur l'environnement (BAPE) and reiterates its commitment to working closely with the community, environmental groups, and authorities for the success of Falco's Horne 5 Project (" Falco's Horne 5 Project " or the " Project" ).

This information period, which was held from April 24 to June 10, 2024, allowed citizens, groups, the municipality and organizations to learn about the various environmental, economic and social aspects of the Project. During this period, it was also possible to make requests for public consultation or mediation to the Minister of the Environment, the Fight against Climate Change, Wildlife and Parks.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa Chief Executive Officer, will participate in a fireside chat at the 2024 Goldman Sachs Global Healthcare Conference in Miami, Florida on Wednesday, June 12, 2024 at 11:20am ET . Management will also host one-on-one investor meetings. Please find additional details about the event below.

2024 Goldman Sachs Annual Global Healthcare Conference
Format: Fireside Chat
Presentation Date: Wednesday, June 12, 2024 , 11:20am ET
Webcast: Click Here

Relmada management will also be available for one-one-one investor meetings during the conference. Please contact your Goldman Sachs representative to schedule a meeting.

The webcast can also be accessed via the Investors section of the Relmada website at https://www.relmada.com/for-investors . An archived replay will be available for 90 days following the conclusion of the event.

About REL-1017

REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the adjunctive treatment of major depressive disorder (MDD). Relmada's ongoing clinical research program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. The development program for REL-1017 as an adjunctive treatment for MDD includes two Phase 3 randomized, double-blind, placebo-controlled studies, Reliance II (Study 302) and Relight (Study 304). Reliance II and Relight have the same key study design parameters.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com .

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of clinical trial results to demonstrate statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of the 310 open-label study to accurately reflect the results of the ongoing 302 and 304 blinded, randomized and controlled studies, failure of the planned psilocybin Phase 1 and Phase 2a trials to be successfully carried out, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@LifeSciAdvisors.com

Media Inquiries:
Corporate Communications
media@relmada.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/relmada-therapeutics-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-conference-302167986.html

SOURCE Relmada Therapeutics, Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Interval	Drill Hole #	From (m)	To (m)	Width (m)	Au+PGE (g/t)	Ag (g/t)	Cu (%)	Mo (%)	Ni (%)	V (%)	V2O5 (%) **	Zn (%)
3a	NAG96-03	12.00	18.00	6.00	0.11	6.76	0.11	0.04	0.19	0.26	0.47	0.13
3b	NAG96-03	37.35	38.35	1.00	0.09	3.40	0.07	0.02	0.13	0.24	0.43	0.02
3c	NAG96-03	43.00	54.00	11.00	0.24	6.63	0.14	0.04	0.24	0.26	0.46	0.03
7a	NAG96-07	80.10	88.19	8.09	0.05	4.10	0.05	0.02	0.15	0.12	0.22	0.72
7b	NAG96-07	100.00	104.00	4.00	0.04	3.47	0.07	0.02	0.09	0.10	0.28	0.60
7c	NAG96-07	108.00	120.40	12.40	0.08	3.67	0.10	0.03	0.19	0.19	0.24	0.14
1a*	NAG96-01	5.20	10.20	5.00	0.06	7.76	0.09	0.03	0.14	0.13	0.23	1.12
1b*	NAG96-01	34.30	39.40	5.10	0.04	4.66	0.08	0.03	0.12	0.16	0.29	0.79
1c*	NAG96-01	47.00	47.90	0.90	0.02	23.73	0.04	0.00	0.03	0.03	0.06	0.29
1d*	NAG96-01	52.40	88.90	35.69	0.01	0.65	0.12	0.03	0.25	0.17	0.31	0.63
2a*	NAG96-02	9.25	19.00	9.75	0.05	6.15	0.07	0.02	0.13	0.10	0.19	0.59
2b*	NAG96-02	25.20	26.18	0.98	0.03	3.71	0.05	0.03	0.04	0.11	0.19	1.14
2c*	NAG96-02	46.65	85.08	38.43	0.11	6.12	0.12	0.03	0.21	0.21	0.37	0.69
2d*	NAG96-02	105.45	108.05	2.60	0.23	3.74	0.09	0.03	0.19	0.29	0.51	0.09

	Total Votes	% of Votes Cast
Votes in Favour Votes Against	51,217,885 279,704	99.46% 0.54%
Total Votes Cast	51,497,589	100%

Name	Votes in Favour	%	Votes Withheld	%
Mark Brennan	50,021,594	99.07%	471,462	0.93%
Robert Campbell	50,366,186	99.75%	126,870	0.25%
Christopher Jones	50,366,186	99.75%	126,870	0.25%
Kurt Menchen	50,366,186	99.75%	126,870	0.25%
Rui Botica Santos	50,366,186	99.75%	126,871	0.25%
Robert Sellars	50,366,186	99.75%	126,870	0.25%

	Total Votes	% of Votes Cast
Votes in Favour	51,278,483	99.57%
Votes Withheld	219,106	0.43%
Total Votes Cast	51,497,589	100%

SAMPLE	Au	Pt	Pd	Ag	Cu	Mo	Ni	V	V₂O₅	Zn
	(g/t)	(g/t)	(g/t)	(g/t)	(%)	(%)	(%)	(%)	(%) **	(%)
NF22 001	0.01	0.00	0.01	2.16	0.03	0.00	0.03	0.01	0.02	0.01
NF22 002	0.02	0.01	0.08	7.93	0.24	0.11	0.24	0.33	0.59	0.04
NF22 012	0.03	0.02	0.09	7.85	0.14	0.03	0.17	0.21	0.38	0.07
NF22 013	0.01	0.01	0.02	2.43	0.04	0.05	0.04	0.14	0.25	13.05
NF22 014	0.02	0.02	0.12	11.70	0.23	0.10	0.21	0.28	0.50	0.16
NF22 015	0.02	0.00	0.23	8.14	0.25	0.00	0.37	0.03	0.06	0.11
NF22 016	0.06	0.01	0.04	15.40	0.06	0.05	0.04	0.15	0.27	0.01
NF22 017	0.11	0.01	0.04	10.50	0.07	0.02	0.05	0.18	0.32	4.31
NF22 018	0.00	0.00	0.05	7.30	0.04	0.03	0.04	0.16	0.28	0.02
NF22 019	0.00	0.13	0.04	10.20	0.01	0.03	0.01	0.21	0.37	0.02
NF22 020	0.05	0.02	0.54	18.45	0.49	0.04	0.08	0.29	0.52	0.10
NF22 021	0.09	0.07	0.27	11.90	0.42	0.09	0.28	0.37	0.67	0.07
NF22 022	0.24	0.02	0.22	3.18	0.15	0.01	0.29	0.36	0.64	0.08
NF22 024	0.00	0.03	0.05	1.76	0.13	0.05	0.21	0.31	0.54	0.06
NF22 025	0.00	0.02	0.06	2.30	0.13	0.04	0.48	0.26	0.47	0.02
NF22 026	0.01	0.07	0.09	2.26	0.16	0.03	0.26	0.20	0.35	0.22
NF22 027	0.03	0.03	0.11	3.59	0.19	0.03	0.20	0.18	0.32	0.03
NF22 028	0.01	0.01	0.11	2.78	0.22	0.03	0.34	0.21	0.37	0.93
NF22 029	0.00	0.03	0.07	4.95	0.17	0.04	0.11	0.22	0.40	0.03
NF22 030	0.00	0.04	0.06	5.74	0.18	0.02	0.06	0.26	0.47	0.05
NF22 031	0.01	0.01	0.08	3.23	0.14	0.05	0.17	0.17	0.30	0.03
NF22 032	0.00	0.02	0.12	3.24	0.14	0.02	0.14	0.38	0.67	0.02
NF22 033	0.01	0.00	0.02	7.23	0.22	0.03	0.21	0.16	0.28	0.82
NF22 034	0.01	0.01	0.08	7.70	0.40	0.19	0.21	0.26	0.47	0.11
NF22 035	0.01	0.00	0.00	6.87	0.44	0.03	0.33	0.20	0.36	0.01
NF22 036	0.02	0.14	0.10	1.81	0.17	0.04	0.35	0.50	0.89	0.02
NF22 037	0.03	0.01	0.02	2.72	0.13	0.03	0.13	0.14	0.25	0.43
NF22 038	0.03	0.06	0.04	4.10	0.17	0.08	0.20	0.41	0.74	0.02
NF22 039	0.04	0.03	0.09	6.74	0.31	0.04	0.13	0.22	0.40	0.71
NF22 040	0.02	0.01	0.03	6.32	0.23	0.03	0.24	0.32	0.58	0.03
NF22 041	0.03	0.01	0.06	4.99	0.22	0.07	0.30	0.27	0.48	0.02
NF22 042	0.21	0.03	0.01	4.44	0.15	0.06	0.46	0.40	0.71	0.01
NF22 043	0.01	0.00	0.13	16.00	0.31	0.02	0.26	0.12	0.21	0.10
NF22 044	0.03	0.02	0.05	5.34	0.25	0.04	0.36	0.24	0.43	0.01
NF22 045	0.26	0.03	0.15	2.05	0.14	0.05	0.25	0.30	0.54	0.05
NF22 201	0.13	0.03	0.21	44.50	1.09	0.03	0.14	0.28	0.49	1.38
NF22 202	0.02	0.02	0.03	15.35	0.37	0.07	0.22	0.31	0.56	0.03
NF22 203	0.01	0.00	0.05	12.35	0.05	0.04	0.05	0.14	0.24	0.18
NF22 204	0.01	0.00	0.05	8.72	0.07	0.03	0.06	0.16	0.29	0.27
NF22 205	0.00	0.01	0.04	4.72	0.06	0.01	0.16	0.12	0.21	0.13
NF22 206	0.01	0.00	0.07	11.00	0.13	0.03	0.18	0.25	0.44	1.20
NF22 207	0.00	0.00	0.03	7.75	0.18	0.05	0.08	0.18	0.32	0.67
NF22 208	0.01	0.04	0.02	10.65	0.34	0.02	0.27	0.27	0.47	0.22
NF22 209	0.00	0.00	0.00	1.20	0.03	0.00	0.01	0.02	0.04	0.01
NF22 210	0.00	0.01	0.02	2.65	0.07	0.01	0.15	0.08	0.14	0.01

StrategX Elements Corp. Announces $1.5M Private Placement Resulting in Creation of a Control Person

StrategX Elements Investor Kit

GET YOUR FREE INVESTOR KIT

Overview

Company Highlights

Key Projects

Melville Peninsula, Nunavut

Melville Overview

Nagvaak Project

Project Highlights:

MEL Project

Project Highlights:

Tasijuaq Project

Project Highlights:

East Arm, Northwest Territories

East Arm Overview

Project 939

Project Highlights:

Project EA South

Project Highlights:

Management Team

Darren Bahrey - CEO & President, Founder

Paula Caldwell St-Onge - Independent Director

Ryan McEachern - Independent Director

Andrea Yuan - Chief Financial Officer

Ariel Cobangbang - IR & Marketing Communications

Adam Vary - Chief Technical

Latest News

StrategX Elements Investor Kit

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

TOP STOCKS